{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:41:47Z","timestamp":1777934507996,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T00:00:00Z","timestamp":1603584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Brentuximab vedotin (Bv) has been approved for the treatment of Refractory\/Relapsed (R\/R) Anaplastic Large Cell Lymphomas (ALCL) and cutaneous T-Cell Lymphomas, but is also effective in other CD30+ malignancies. We report here the outcomes of patients with various R\/R Peripheral T Cell Lymphoma (PTCL) treated with Bv in real life practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This was a retrospective, single-center study based on medical records of patients with R\/R PTCL treated either with Bv alone or in combination with chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 27 patients treated with Bv, neutropenia was the main serious adverse event observed in particular when Bv was used as combination treatment. The complete Response Rates (CRR) was 40.7%; it was significantly improved when Bv was used as combination treatment. The majority of eligible patients (7\/10) underwent Stem Cell Transplantation. Median Progression Free Survival (PFS) and Overall Survival (OS) were 5.2\u2009months and 12.5\u2009months respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our current study shows that Bv used in combination with chemotherapy provides a high CRR and thereby allows SCT in R\/R PTCL. The use of Bv treatments in this setting warrants further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220968615","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:56:57Z","timestamp":1603673817000},"page":"1730-1735","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Brentuximab vedotin in real life, a seven year experience in patients with refractory\/relapsed CD30+  T cell lymphoma"],"prefix":"10.1177","volume":"27","author":[{"given":"Lucie","family":"Oberic","sequence":"first","affiliation":[{"name":"Department of Haematology, IUCT-Oncopole, CHU Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faustine","family":"Delzor","sequence":"additional","affiliation":[{"name":"Pharmacy Department IUCT (Institut Universitaire du Cancer) Oncopole, University Hospital Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Protin","sequence":"additional","affiliation":[{"name":"Department of Haematology, IUCT-Oncopole, CHU Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Perriat","sequence":"additional","affiliation":[{"name":"Pharmacy Department IUCT (Institut Universitaire du Cancer) Oncopole, University Hospital Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Laurent","sequence":"additional","affiliation":[{"name":"Department of Pathology, IUCT-Oncopole, CHU Toulouse, Toulouse, France"},{"name":"Centre de Recherches en Canc\u00e9rologie de Toulouse (CRCT), Team 9, INSERM UMR1037, Universit\u00e9 de Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana\u00efs","family":"Grand","sequence":"additional","affiliation":[{"name":"Pharmacy Department IUCT (Institut Universitaire du Cancer) Oncopole, University Hospital Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Marie","family":"Canonge","sequence":"additional","affiliation":[{"name":"Pharmacy Department IUCT (Institut Universitaire du Cancer) Oncopole, University Hospital Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Borel","sequence":"additional","affiliation":[{"name":"Department of Haematology, IUCT-Oncopole, CHU Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Gauthier","sequence":"additional","affiliation":[{"name":"Department of Haematology, IUCT-Oncopole, CHU Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Ysebaert","sequence":"additional","affiliation":[{"name":"Department of Haematology, IUCT-Oncopole, CHU Toulouse, Toulouse, France"},{"name":"Centre de Recherches en Canc\u00e9rologie de Toulouse (CRCT), Team 9, INSERM UMR1037, Universit\u00e9 de Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3083-5784","authenticated-orcid":false,"given":"Florent","family":"Puisset","sequence":"additional","affiliation":[{"name":"Pharmacy Department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, Toulouse, France"},{"name":"Centre de Recherches en Canc\u00e9rologie de Toulouse (CRCT), Team 14, INSERM UMR1037, Universit\u00e9 de Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,10,25]]},"reference":[{"key":"bibr1-1078155220968615","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"bibr2-1078155220968615","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu443"},{"key":"bibr3-1078155220968615","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1270202"},{"key":"bibr4-1078155220968615","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0039"},{"key":"bibr5-1078155220968615","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 M Economic and Public Health Assessment Division. ADCETRIS 50 mg, powder for concentrate for solution for infusion TRANSPARENCY COMMITTEE OPINION 6 March 2013. Published online March 6, 2013."},{"key":"bibr6-1078155220968615","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"bibr7-1078155220968615","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.3982.3982"},{"key":"bibr8-1078155220968615","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0098"},{"key":"bibr9-1078155220968615","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2"},{"key":"bibr10-1078155220968615","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.100784"},{"key":"bibr11-1078155220968615","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186577"},{"key":"bibr12-1078155220968615","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542142"},{"key":"bibr13-1078155220968615","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"bibr14-1078155220968615","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2018.07.004"},{"key":"bibr15-1078155220968615","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850"},{"key":"bibr16-1078155220968615","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-815183"},{"key":"bibr17-1078155220968615","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-020-00561-w"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220968615","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220968615","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220968615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:24:05Z","timestamp":1777688645000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220968615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,25]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1177\/1078155220968615"],"URL":"https:\/\/doi.org\/10.1177\/1078155220968615","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,25]]}}}